Abstract
The duration and nature of immunity generated in response to SARS-CoV-2 infection is unknown. Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARS-CoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The timescale of protection is a critical determinant of the future impact of the pathogen. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. The dynamics of immunity and nature of protection are relevant to discussions surrounding therapeutic use of convalescent sera as well as efforts to identify individuals with protective immunity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV-1, MERS-CoV and human endemic coronaviruses (HCoVs). We reviewed 1281 abstracts and identified 322 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While studies of SARS-CoV-2 are necessary to determine immune responses to it, evidence from other coronaviruses can provide clues and guide future research.
Key Questions for SARS-CoV-2
What are the kinetics of immune responses to infection?
Do people who have more severe disease mount stronger antibody responses after infection?
How do antibody responses vary between different types of antibodies or as measured by different assays?
How does the presence of antibodies impact the clinical course and severity of the disease?
Is there cross-reactivity with different coronaviruses?
Does cross-reactivity lead to cross-protection?
Will infection protect you from future infection?
How long will immunity last?
What are correlates of protection?
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported [in part] by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health. DATC was supported by the US National Institutes of Health award number R01-AI114703-01.APW is funded by a Career Award at the Scientific Interface from the Burroughs Wellcome Fund and by the National Library of Medicine of the National Institutes of Health under award number DP2LM013102. IRB was supported by the John A Watson Faculty Scholar fellowship.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We have made all data related to our systematic review and pooled analyses available at the following archive: https://doi.org/10.5281/zenodo.3751566
